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Abstract: Parkinson’s disease (PD) is a chronic progressive and irreversible disease and the second
most common neurodegenerative disease worldwide. In Spain, it affects around 120.000–150.000
individuals, and its prevalence is estimated to increase in the future. PD has a great impact on
patients’ and caregivers’ lives and also entails a substantial socioeconomic burden. The aim of
the present study was to examine the current situation and the 10-year PD forecast for Spain in
order to optimize and design future management strategies. This study was performed using the
modified Delphi method to try to obtain a consensus among a panel of movement disorders experts.
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According to the panel, future PD management will improve diagnostic capacity and follow-up, it
will include multidisciplinary teams, and innovative treatments will be developed. The expansion of
new technologies and studies on biomarkers will have an impact on future PD management, leading
to more accurate diagnoses, prognoses, and individualized therapies. However, the socio-economic
impact of the disease will continue to be significant by 2030, especially for patients in advanced
stages. This study highlighted the unmet needs in diagnosis and treatment and how crucial it is to
establish recommendations for future diagnostic and therapeutic management of PD.
Keywords: diagnosis; economic impact; epidemiology; management; mortality; Parkinson’s disease;
quality of life; Spain; treatment
1. Introduction
Parkinson’s disease (PD) is the second most common neurodegenerative disease
after Alzheimer’s disease [1] and affects around 120.000–150.000 individuals in Spain [2].
Excellent symptomatic treatment is available, although no neuroprotective medication
has been found so far. Even though the average age of onset is 60 years, the number of
diagnoses under the age of 50 is increasing [3]. Given that PD prevalence increases with
age [3], and considering the increase of life expectancy, the number of people affected by
PD is predicted to strongly increase in the future [4].
PD is characterized by motor symptoms including bradykinesia, resting tremor and
muscle rigidity, but also by non-motor symptoms. These include cognitive impairment,
mood disorders and depression, and may appear even at early disease stages [5,6]. More-
over, non-motor symptoms are often misdiagnosed because PD is mainly diagnosed on
clinical motor symptomatology, following the United Kingdom Parkinson’s Disease Society
Brain Bank (UK-PDSBB) criteria [7,8]. The Movement Disorder Society’s clinical diagnostic
criteria for PD (MDS-PD) are intended for use specifically in research; however, they can
be used as a general guide for clinical diagnosis. MDS-PD include supportive criteria apart
from motor symptoms [9]. Non-motor symptoms in the prodromal phase are usually not
very specific (except for rapid eye movement [REM] sleep behavior disorder [RBD]), so
they are not strong enough by themselves to reach a PD diagnosis. Recent studies have
allowed PD diagnosis at prodromal stages in individuals with risk factors (hyposmia,
depression and constipation, among others) or RBD itself [10]. PD’s heterogeneous presen-
tation reflects its complex and multifactorial etiogenesis, its diverse clinical course [11] and
probably a different pathogenic mechanism. Therefore, PD management is a major chal-
lenge because clinical response to treatment is also heterogeneous and disease treatment
has to be personalized.
There is no first-choice treatment for PD management, although many pharmacologi-
cal and non-pharmacological strategies are available. Among pharmacological treatments,
levodopa, dopaminergic agonists (DA), catechol-O-methyltransferase inhibitors (COMTI)
and monoaminooxidase B inhibitors (MAOI-B) are the most common therapies for PD,
used both alone or in combination [3]. Since several motor, non-motor symptoms and
related complications must be treated, PD management is often complex.
As a chronic progressive disease, PD has a great impact on patients’ and caregivers’
private, social and professional lives. PD caused more than 200,000 deaths and 3.2 million
disability-adjusted life-years (DALYs) worldwide in 2016, and more than 4000 deaths and
54,175 DALYs in Spain [12]. Moreover, it also causes substantial societal burden and entails
an important economic impact [13].
Considering the high incidence of the disease, its increased prevalence due to popula-
tion aging and the unmet needs regarding diagnosis and treatment, it is crucial to better
understand PD management to optimize and design future strategies. Thus, the aim of the
PARKINSON 2030 project was to discuss and reach a consensus using the Delphi method
(a process used to arrive at a group opinion or decision by surveying a panel of experts
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in which the experts respond to several rounds of questionnaires, and the responses are
aggregated and shared with the group after each round) among a panel of experts in move-
ment disorders on the current situation, their 10-year forecast of the general management
of PD in daily clinical practice and to establish recommendations on the diagnostic and
therapeutic management of PD.
2. Materials and Methods
We specifically used a modified Delphi method (a group consensus strategy that
systematically uses literature reviews, opinions of stakeholders and the judgment of experts
within a field to reach agreement) [14–16] to better understand the management and
the socioeconomic burden of PD in Spain. This Delphi approach was carried out in
6 successive phases: creation of an Advisory Committee, definition of criteria to select
panelists, design of the Delphi questionnaire, Delphi survey administration, data collection
and data analysis.
The Advisory Committee included 4 experts in movement disorders, members of the
Study Group of Movement Disorders of the Spanish Neurology Society (Sociedad Española
de Neurología, SEN). The Advisory Committee defined the project and created the first
version of the Delphi questionnaire.
Panelists included were experts in movement disorders from different regions of
Spain. The list of participating panelists is shown in Table S1.
Preparation and Administration of the Questionnaire and Data Analysis
A literature search that included guidelines, reviews and other types of critical synthe-
sis of scientific literature, as well as a bottom-up search from the main references to identify
other papers of interest was carried out, and the initial questionnaire developed. The ques-
tionnaire addressed nine topics: the epidemiology of PD, the pathophysiology of PD, PD’s
impact on patients and caregivers, PD diagnosis, PD follow-up, PD treatment, the economic
impact of PD, the current and future situation of PD and the role of patient and caregiver
associations. The initial version of the questionnaire was validated by 14 additional experts
in movement disorders, acting as the National Committee of experts (Figure S1). The ques-
tionnaire was held to two rounds of voting between October–December 2019 (first wave)
and September–November 2020 (second wave). Panelists completed the questionnaire
through an online platform that ensured data anonymity and confidentiality.
All questions about the current situation used a 4-level scale, which varied depending
on the question (never, rarely, often, always; or, strongly disagree, disagree, agree, strongly
agree; or, not important, not very important, important, very important; or, not useful, not
very useful, useful, very useful; or, no impact, little impact, quite some impact, a lot of
impact). All questions referring to future trends used a nine-point Likert-type ordinal scale,
divided in three categories: 1 to 3 (it will decrease), 4 to 6 (it will not change) and 7 to 9 (it
will increase). When ≥70% of panelists agreed in one category of response, that item was
considered to have reached “consensus” on that category. Otherwise, the item was stated
as “undetermined” and sent for a second round of votes, together with all comments made
by panelists in face-to-face meetings.
Between the two rounds of voting, panelists attended 7 face-to-face local meetings
moderated by the members of the National Committee of experts. In these meetings, the
results of wave 1 were presented and discussed, and the items of the questionnaire to
include in wave 2 were agreed upon. Although 12 meetings were planned, due to the state
of alarm decree by COVID-19 in March 2020, only 7 meetings were held. All items that did
not reach consensus in the first wave were included in the second wave.
The final results of the Delphi survey were further evaluated and discussed by the
Advisory and National Committees.
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3. Results
3.1. Panelists’ Description
Seventy-five (75) experts in movement disorders from different regions of Spain were
included in the panel, and a mean of 14.3 years of experience was reported. Regarding
the type of work center, 74% had practiced in tertiary centers, while only 4% worked in
primary care centers. A full description of the participant panelists can be found in the
Supplementary Table S2.
3.2. Epidemiology of PD—Etiopathogenesis
Overall, 92% and 84% of the experts consulted considered that prevalence and inci-
dence of PD will increase by 2030, respectively. The trend towards 2030 in the percentage
of PD patients diagnosed at <50 years was not agreed upon by the experts: 67% indicated
that this percentage will not change and 33% indicated that it will increase. Regarding
the etiopathogenesis of the disease, 73% of experts considered that the identification of
non-modifiable PD risk factors will not progress in 2030, while knowledge of modifiable
PD risk factors will not be improved (76%) (data not shown).
3.3. Prognostic Factors
According to the experts, the factors that are currently widely or always used as
prognostic factors for PD include phenotype with axial involvement (100%), cognitive
impairment (99%), early presence and severity of motor complications (99%), age at onset
(93%), neuropsychiatric disorders (92%) and Hoehn & Yahr clinical stage (85%). Experts
reached a consensus that, by 2030, only the assessment of neuropsychiatric disorders as
a PD prognostic factor will increase. Among the prognostic factors less used nowadays,
the experts affirmed that the use of genetic testing, structural imaging, CSF (cerebrospinal
fluid) biomarkers and serum molecular markers will increase in the future (Table 1).
Table 1. Prognostic factors: present and future (consensus after both rounds).
Prognostic Factors
YEAR 2020 TREND 2030
Currently, This Prognostic Factor for PD Is Used . . . By 2030, the Use of This Prognostic Factor for PD Will . . .
Rarely/Never Often/Always Consensus H = N Consensus
Phenotype with axial involvement
(blockings and balance problems) 0% 100% Often/Always 0% 63% 37% Undetermined
Cognitive impairment 1% 99% Often/Always 0% 59% 41% Undetermined
Early presence and severity of motor
complications 1% 99% Often/Always 1% 73% 26% Not change
Age at onset 7% 93% Often/Always 0% 76% 24% Not change
Neuropsychiatric disorders
(depression, apathy, hallucinations) 8% 92% Often/Always 0% 48% 52% Undetermined
Hoehn & Yahr clinical stage 15% 85% Often/Always 19% 77% 5% Not change
Autonomic alterations 47% 53% Undetermined 3% 43% 55% Undetermined
Sleep disorders (RBD associated to PD) 68% 32% Undetermined 1% 60% 39% Undetermined




93% 7% Rarely/Never 1% 23% 76% Increase N
Genetic alterations 91% 9% Rarely/Never 1% 6% 93% Increase N
Severe hyposmia or anosmia 89% 11% Rarely/Never 0% 87% 13% Not change
Degree of alteration in DATSCAN and
PET studies, among others 87% 13% Rarely/Never 6% 45% 49% Undetermined
Use of structural imaging to determine
the degree of alteration (e.g., atrophy in
certain areas as predictors of dementia,
etc.)
84% 16% Rarely/Never 5% 17% 78% Increase N
All panelists (n = 75) answered all questions. The percentage of panelists in each category and consensus after the second round of votes
are shown. Bold % indicates that 70% consensus was achieved. CSF: Cerebrospinal fluid. DATSCAN: Dopamine Transporter Scan. PD:
Parkinson’s disease. PET: Positron emission tomography. RBD: Rapid eye movement sleep behavior disorder or REM behavior disorder. H:
it will decrease; =: it will not change; N: it will increase.
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3.4. Medical Specialties Involved in the Management of the PD Patient
Nowadays, a poorly multidisciplinary approach is applied in the treatment of PD
and it is generally limited to the neurologists specialized in PD and general neurologists,
with no significant involvement of other disciplines. However, panelists agreed that the
role of movement disorder specialists in nursing would gain importance especially in the
treatment of PD patients with advanced stages and in patients under advanced therapy
(Figure 1).
Figure 1. Relevance of medical specialties: present and future. For the current situation, percentages of panelists who considered
a given specialty “Relevant” or “Very relevant” in each stage are shown. For the trend by 2030, percentages of panelists who
predicted a decrease (H), no change (=) or an increase (N) for the relevance of each specialty in each stage are shown.
3.5. Diagnosis
Overall, 83% of the experts agreed with the definition of the diagnosis of the MDS
criteria [7,8]; however, there was no consensus on the future trend (Table 2). Among the
diagnostic tools currently applied, only the use of functional neuroimaging (78%) was
predicted to increase by 2030. Atypical signs and non-motor symptoms are also currently
considered key aspects for PD diagnosis, by 95% and 79% of panelists, respectively, without
consensus on future trends. Regarding other biomarkers experts suggest that only the use
of biochemical markers (74%) and genetic criteria (70%) will increase by 2030 (Table 2).
By 2030, 94% of panelists considered that the time taken to obtain a diagnosis will
decrease compared to today, and 84% agreed that the percentage of misdiagnosed patients
will decrease (data not shown).
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Table 2. Criteria, scales and/or tests for the diagnosis of PD: present and future (consensus after both rounds).
Items
YEAR 2020 TREND 2030
Diagnosis of PD Is Currently Based on This
Criterium, Marker, Parameter or Test.
By 2030, the Use of This Criterium, Marker,




Agree Consensus H = N Consensus
Atypical signs 5% 95% Agree 0% 70% 30% Not change
New MDS criteria 17% 83% Agree 5% 56% 39% Undetermined
Non-motor symptoms (sense of smell . . . ) 21% 79% Agree 2% 36% 63% Undetermined
Functional neuroimaging (SPECT, PET, heart
scintigraphy) 21% 79% Agree 0% 22% 78% Increase N
Pharmacological tests (levodopa test,
apomorphine test) 32% 68% Undetermined 8% 85% 7% Not change
Neurophysiological markers 100% - Disagree 13% 72% 15% Not change
Hyposmia test 99% 1% Disagree 15% 73% 12% Not change
Biochemical markers 97% 3% Disagree 3% 23% 74% Increase N
Sleep analysis scales (PSG) 95% 5% Disagree 10% 73% 17% Not change
Neurosonography 95% 5% Disagree 11% 49% 39% Undetermined
Genetic criteria 93% 7% Disagree 0% 30% 70% Increase N
Structural neuroimaging 93% 7% Disagree 4% 53% 43% Undetermined
All panelists (n = 75) answered all questions. Percentages of panelists in each category and consensus after the second round of votes are
shown. Bold % indicates that 70% consensus was achieved. MDS: Movement Disorder Society. PD: Parkinson’s disease. PET: Positron
emission tomography. PSG: polysomnography. SPECT: Single-photon emission computed tomography. H: it will decrease; =: it will not
change; N: it will increase.
3.6. Follow-Up
Concerning the tools used in the clinical follow-up, the Hoehn & Yahr scale (88%)
and the scale of the Movement Disorders Society—Unified Parkinson’s disease rating
scale (MDS-UPDRS) (77%) are predicted to be used in the same frequency in the future. In
contrast, panelists agreed that several tools not widely used nowadays will be progressively
implemented by 2030. These include wearable, non-wearable, hybrid and smartphone
sensors (94%), pharmacogenetics (72%) and biochemical markers (71%) (Table 3). There is
currently no consensus on the contribution of new technologies to the remote monitoring
of PD patients, however, panelists agreed that their contribution will increase by 2030
(Supplementary Figure S2).
Table 3. Criteria, scales and/or tests for the follow-up of PD: present and future (percentages of respondents after both rounds).
Items
YEAR 2020 TREND 2030
Follow-Up of PD Is Currently Based on This Scale
or Test.
By 2030, the use of This Scale or Test During




Agree Consensus H = N Consensus
Hoehn & Yahr scale 11% 89% Agree 6% 88% 6% Not change
MDS-UPDRS 19% 81% Agree 5% 77% 18% Not change
Cognitive impairment scales 20% 80% Agree 0% 55% 45% Undetermined
Wearing-off assessment scales 24% 76% Agree 2% 67% 31% Undetermined
Scales measuring impulse control behaviors 25% 75% Agree 0% 57% 43% Undetermined
Patient diary 27% 73% Agree 5% 53% 42% Undetermined
Dyskinesia rating scales 33% 67% Undetermined 3% 71% 26% Not change
Quality of life scales 37% 63% Undetermined 0% 56% 44% Undetermined
Motor symptoms scales 39% 61% Undetermined 0% 69% 31% Undetermined
Non-motor symptoms scales 43% 57% Undetermined 0% 39% 61% Undetermined
Disability scales 45% 55% Undetermined 0% 60% 40% Undetermined
Neuropsychiatric disorders scales 49% 51% Undetermined 0% 52% 48% Undetermined
Pharmacogenetics 100% - Disagree 3% 25% 72% Increase N
Biochemical markers 99% 1% Disagree 1% 28% 71% Increase N
Inflammation markers 97% 3% Disagree 3% 42% 55% Undetermined
Neurosonography 96% 4% Disagree 10% 57% 33% Undetermined
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Table 3. Cont.
Items
YEAR 2020 TREND 2030
Follow-Up of PD Is Currently Based on This Scale
or Test.
By 2030, the use of This Scale or Test During




Agree Consensus H = N Consensus
Structural neuroimaging 95% 5% Disagree 6% 52% 42% Undetermined
Wearable, non-wearable, hybrid and
smartphone sensors 93% 7% Disagree 0% 6% 94% Increase N
Functional neuroimaging 91% 9% Disagree 1% 37% 62% Undetermined
Pharmacological tests (levodopa test,
apomorphine test) 88% 12% Disagree 17% 80% 3% Not change
Sleep analysis scales 87% 13% Disagree 0% 60% 40% Undetermined
Gait assessment scales 76% 24% Disagree 2% 60% 38% Undetermined
All panelists (n = 75) answered all questions. Percentages of panelists in each category and consensus after the second round of votes are
shown. Bold % indicates that 70% consensus was achieved. MDS-UPDRS: Movement Disorder Society—Unified Parkinson’s Disease
Rating Scale. H: it will decrease; =: it will not change; N: it will increase.
3.7. Treatment
According to the experts, the use of the currently most frequent monotherapy treat-
ments for non-fluctuating patients (MAOI, DA and levodopa < 600 mg) will not change by
2030. Although it did not reach consensus, panelists observed a trend to decrease in the use
of levodopa at low–moderate doses (<600 mg) (35%) and anticholinergics in monotherapy
(35%) by 2030. In addition, a trend to increase in the use of safinamide in monotherapy
(56%) was observed, while no increase for other MAOI agents in monotherapy was pre-
dicted (Table 4). Although experts did not agree, a trend to increase the combination of
levodopa + safinamide (from 8.7% to 63%) and DA + safinamide (from 4.2% to 51%) was
observed, which was not observed for other MAOI agents in combination (6% in the future
for both combinations). The use of three-drug combination will also remain unchanged in
the future. Finally, a trend to increase the combination levodopa + safinamide + DA (from
6.9% to 59%) was observed.
Table 4. Treatment by patient profile: future trends.
TREATMENT TREND 2030
By 2030, the Use of This Treatment for
Non-Fluctuating Patients Will . . . H = N Consensus
Non-pharmacological treatment alone a 10% 76% 14% Not change
Monotherapy
MAOI b 13% 88% 0% Not change
DA c 22% 76% 1% Not change
Levodopa (<600 mg) 14% 75% 11% Not change
Anticholinergics 35% 65% 0% Undetermined
Levodopa (>600 mg) 35% 61% 4% Undetermined
MAOI d 1% 43% 56% Undetermined
Two-Drug Combination
Levodopa + MAOI b 10% 85% 6% Not change
MAOI b + DA 17% 78% 6% Not change
Levodopa + DA c 21% 75% 4% Not change
Levodopa + COMTI 11% 70% 19% Not change
MAOI d +DA 3% 46% 51% Undetermined
Levodopa + MAOI d 0% 38% 63% Undetermined
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Table 4. Cont.
TREATMENT TREND 2030
By 2030, the Use of This Treatment for
Non-Fluctuating Patients Will . . . H = N Consensus
Three-Drug Combination
MAOI b + DA + levodopa 15% 83% 1% Not change
COMTI +DA + levodopa 11% 77% 11% Not change
MAOI d +DA + levodopa 6% 48% 46% Undetermined
Polytherapy
≥4 drugs 8% 80% 11% Not change
By 2030, the Use of This Treatment for Fluctuating
Patients Will . . . H = N Consensus
Monotherapy
Levodopa (<600 mg) 27% 72% 1% Not change
AD c 30% 69% 1% Undetermined
Levodopa (>600 mg) 34% 63% 3% Undetermined
Two-Drug Combination
Levodopa + AD 10% 83% 7% Not change
Levodopa + COMTI 1% 79% 20% Not change
Levodopa + MAOI b 23% 75% 3% Not change
Levodopa + MAOI d 1% 35% 63% Undetermined
Three-Drug Combination
MAOI b +DA + levodopa 13% 79% 8% Not change
COMTI +DA + levodopa 1% 79% 20% Not change
MAOI d +DA + levodopa 0% 41% 59% Undetermined
Polytherapy
≥4 drugs 3% 77% 20% Not change
By 2030, the Use of This Treatment in Advanced
Therapy Will . . . H = N Consensus
DBS + other pharmacological treatments 3% 21% 76% Increase N
Carbidopa/levodopa (enteral) + other pharmacological
treatments 7% 25% 68% Undetermined
Apomorphine s.c. + other pharmacological treatments 3% 45% 52% Undetermined
All panelists (n = 75) answered all questions. Percentages of panelists in each category and consensus after the second round of votes are
shown. Bold % indicates that 70% consensus was achieved. COMTI: catechol-O-methyltransferase inhibitors. DA: dopaminergic agonists.
DBS: deep brain stimulation. MAOI: monoaminooxidase inhibitors. s.c.: subcutaneous. a Physiotherapy, speech therapy, rehabilitation, etc.
b Rasagiline, Selegiline. c Rotigotine, Ropinirole, Pramipexole. d Safinamide. H: it will decrease; =: it will not change; N: it will increase.
Up to 3.9% of non-fluctuating patients are currently treated with polytherapy (≥4 drugs)
with no predicted changes in the future.
Overall, treatment of fluctuating patients remains unchanged in the future (Table 4).
Although it did not reach consensus, we observed a trend to increase in the use of
safinamide in combination with levodopa (63% in the future) or in combination with
DA + levodopa (59% in the future), not observed when other MAOI agents are considered
in combination with levodopa (3%) or in combination with DA + levodopa (8%) (Table 4).
Only 20% of the experts consider that the combination COMTI + DA + levodopa will
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increase. As expected, polytherapy is frequent in the treatment of fluctuating patients and
will remain unchanged in the future (77%) (Table 4).
Regarding patients in advanced therapy, deep brain stimulation (DBS) treatment was
the only treatment predicted to increase (76%). Although without consensus, a trend
towards an increased use of apomorphine s.c. or carbidopa/levodopa (enteral) in combi-
nation with other pharmacological treatments (52% and 68%, respectively) was observed
(Table 4).
Just as important as the introduction of drugs in the management of PD patients is the
withdrawal of pharmacological treatments in patients already in palliative care. There is
consensus that the first drugs to be withdrawn at present are anticholinergics (93%) and
amantadine (80%) and similar rates of agreement for the future (92% and 81%, respectively)
were observed. The last drug to be withdrawn is levodopa, either nowadays (91%) or in
the future (89%) (data not shown).
With regard to symptomatology and/or comorbidities as a reason for changing treat-
ment, the experts showed a high degree of agreement that the following are reasons for
changing PD treatment: onset of neuropsychiatric and cognitive disorders; deterioration in
basic activities of daily living (BADL) autonomy; motor symptoms; impaired quality of life;
affective, emotional and volitional disorders; sleep disorders; and autonomic disorders. In
contrast, disorders of other organs outside the central nervous system (CNS) (osteoporosis,
back pain, respiratory disorders) would not be a reason to reconsider treatment, according
to 84% of the experts (Table 5).
The experts showed a high degree of agreement in relation to the statements concern-
ing the change of treatment for PD, except for the item neuroprotective treatments prevail
over symptomatic treatments, which reached a high consensus for disagreement. However,
46% of experts seem to express some confidence that neuroprotective treatment may be
available in the future (Table 5).
In terms of investigational therapies, new formulations of oral levodopa were not
considered useful in the treatment of PD nowadays or in the future, although they showed
a trend to increase. New formulations of levodopa (intraduodenal, inhaled, subcutaneous,
etc.) (86%), antidyskinetic drugs (79%), therapies for non-motor symptoms (dementia,
depression, impulse control disorders [ICD], fatigue, pain, etc.) (79%), therapies to increase
levodopa bioavailability (camicinal, DA-9701, VY-AADC01, etc.) (78%) and new symp-
tomatic drugs (MAO-B, COMTI, agonists, etc.) (70%) were considered to be quite or very
useful in the treatment of PD with a trend of increase by 2030 (Supplementary Figure S3A).
When considering non-pharmacological therapies, the use of ultrasound (High-Intensity
Focused Ultrasound [HIFU], Low-Intensity Focused Ultrasound [LIFU]) (88%) and DBS
(72%) were considered quite or very useful in the treatment of PD and their utility was
expected to increase by 2030. Other therapies (transcranial magnetic stimulation [TMS],
transcranial direct current stimulation [tDCS], caloric vestibular stimulation, etc.) were
considered to be of little or no use and their trend towards 2030 did not change. There
was no consensus on the utility of surgical procedures other than DBS, either now or
by 2030 (Supplementary Figure S3B). Other agents with a possible modifying effect on
the progressive course of the disease such as immunotherapies and regenerative thera-
pies, were considered not applicable nowadays, with no consensus on the trend towards
2030; however, the highest percentage of responses pointed out an increased use by 2030
(Supplementary Figure S3C).
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Table 5. Change/modification of PD treatment: present and future.
Items YEAR 2020 TREND 2030
Onset of These Symptoms and/or Comorbidities
Is a Reason for Changing PD Treatment.
By 2030, the Relevance of These Symptoms
and/or Comorbidities as a Reason to Change
Treatment Will . . .
Symptoms and/or Comorbidities (Strongly)Disagree
(Strongly)
Agree Consensus H = N Consensus
Neuropsychiatric and cognitive disorders a - 100% Agree 0% 55% 45% Undetermined
Deterioration in BADL autonomy - 100% Agree 0% 60% 40% Undetermined
Motor symptoms b - 100% Agree 1% 63% 36% Undetermined
Impaired quality of life 1% 99% Agree 0% 54% 46% Undetermined
Affective, emotional and volitional disorders c 1% 99% Agree 0% 59% 41% Undetermined
Sleep disorders d 5% 95% Agree 0% 62% 38% Undetermined
Autonomic disorders e 9% 91% Agree 0% 54% 46% Undetermined
Disorders of other organs outside the CNS f 84% 16% Disagree 2% 83% 15% Not change





Agree Consensus H = N Consensus
Treatment is started at early stages - 100% Agree 0% 49% 51% Undetermined
Pharmacological treatment is modified when an
impairment of quality of life is observed. - 100% Agree 0% 57% 43% Undetermined
Treatment is changed when cognitive dysfunction
and/or psychotic symptoms appear. 1% 99% Agree 0% 68% 32% Undetermined
Pharmacological treatment is changed when new
motor symptoms appear. 1% 99% Agree 0% 73% 27% Not change
Treatment is modified if lack of response to a new
treatment is observed. 1% 99% Agree 0% 74% 26% Not change
Treatment is changed in case of side effects. 3% 97% Agree 0% 71% 29% Not change
Pharmacological treatment is changed when new
non-motor symptoms appear. 5% 95% Agree 0% 49% 51% Undetermined
Neuroprotective treatments prevail over
symptomatic treatments 96% 4% Disagree 3% 51% 46% Undetermined
All panelists (n = 75) answered all questions. Percentages of panelists in each category and consensus after the second round of votes
are shown. Bold % indicates that 70% consensus was achieved. BADL: basic activities of daily living. CNS: Central nervous system.
PD: Parkinson’s disease. H: it will decrease; =: it will not change; N: it will increase. a Hallucinations, delusions, delusional ideation,
dementia, difficulties in concentration, etc. b Motor fluctuations, bradykinesia, freezing of gait, balance alterations, postural reflex alterations,
dysphagia, hypersalivation, dysarthria, rigidity, etc. c Depression, apathy, anxiety, sexual disorders, etc. d REM behavior disorder, insomnia,
excessive daytime sleepiness, etc. e Constipation, salivation, hypotension, incontinence, erectile dysfunction, sweating, sexual disorders,
swallowing disorders, etc. f Osteoporosis, back pain, respiratory disorders, etc.
3.8. Impact of PD
According to the experts, mental health, social life, quality of life and working life are
affected in early PD patients, and more than 60% of the experts indicate that in 2030 the
impact of these factors will remain unchanged. The same trend is observed among items
considered to have low impact on PD patients in early stages (cognitive performance, au-
tonomy in performing instrumental and basic activities of daily living and life expectancy)
(Figure 2A).
In the advanced PD patient, experts considered that all items are affected by the
disease on patients nowadays, and that this scenario will remain unchanged by 2030 (data
not shown). Furthermore, the level of impact of PD on the caregiver was also high for all
items considered, and more than 60% of experts indicated that this impact will remain
unchanged (Figure 2B).
Regarding economic impact, the experts agreed that currently indirect costs (loss of
productivity, home care and caregiver), second-line therapies and economic burdens have a
high financial impact (Figure 3). Although experts did not reach a consensus, we observed
a general trend towards remaining unchanged or an increase for all items.
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Figure 2. Impact of PD on patients and caregivers: (a) Impact of PD on patients (PD in early stages);
(b) Impact of PD on caregivers.
Figure 3. Economic impact of PD.
3.9. Needs of Management
According to the experts, current needs regarding PD diagnosis include appropriate
information from professionals, shortening the time to obtain a PD diagnosis, rapid referral
to protocolized movement disorder units (MDU) and training primary care professionals
for early detection of motor symptoms suggestive of PD. Satisfaction of all these items
shows a trend to increase in the future, but experts only agreed that improvement will be
seen in shortening the time to obtain PD diagnosis, and rapid referral to specific MDU
(Table 6). Regarding statements of PD follow-up and treatment, all of them were considered
needs nowadays, but no consensus in their future satisfaction was reached for any of the
statements. Nevertheless, a trend of improvement in all items was observed (Table 6).
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Table 6. Needs of PD management: present and future.
Items YEAR 2020 TREND 2030
This Item Is Important in Current Diagnosis of
PD
By 2030, the Importance of This Item on
Diagnosis of PD Will . . .
PD Diagnosis Not (very)important
(Very)
important Consensus H = N Consensus
Appropriate information from professionals 1% 99% Important 0% 37% 63% Undetermined
Shortening the time to obtain PD diagnosis 9% 91% Important 1% 19% 79% Increase N
Rapid referral to protocolized MDU 15% 85% Important 0% 22% 78% Increase N
Training primary care professionals for early
detection of motor symptoms suggestive of PD 9% 81% Important 0% 36% 64% Undetermined
Providing psychological support to the patient,
family and/or caregiver 37% 63% Undetermined 0% 39% 61% Undetermined
Support from movement disorders specialist nurses 59% 41% Undetermined 1% 17% 81% Increase N
Early diagnosis based on non-motor symptoms 69% 31% Undetermined 0% 23% 77% Increase N
PD Follow-Up




Agree Consensus H = N Consensus
Ensuringthe resolution of any doubts the patient
may have. 3% 97% Agree 0% 45% 55% Undetermined
Developing improved coordination between health
professionals and social services 5% 95% Agree 0% 35% 65% Undetermined
Developing greater coordination between the
different levels of health services 8% 92% Agree 0% 33% 67% Undetermined
Improve the patient’s adaptation to the PD evolution 8% 92% Agree 0% 46% 54% Undetermined
Establishing a follow-up protocol in the first months
after diagnosis. 15% 85% Agree 2% 51% 47% Undetermined
Providing legal and medical assistance 15% 85% Agree 0% 50% 50% Undetermined
PD Treatment




Agree Consensus H = N Consensus
Availability of speech therapy sessions to help with
language and information processing 1% 99% Agree 0% 41% 59% Undetermined
Availability of dopaminergic treatment that provides
the benefits of levodopa without worsening motor
complications
3% 97% Agree 1% 34% 64% Undetermined
Availability of occupational therapy that provides
adaptive strategies 4% 96% Agree 0% 44% 56% Undetermined
Availability of global and integrated rehabilitative
treatment that allows less medication intake (number
and dose)
5% 95% Agree 0% 32% 68% Undetermined
Availability of physiotherapy and other alternative
therapies such as hydrotherapy, yoga, pilates or
Tai-Chi
5% 95% Agree 0% 35% 65% Undetermined
Having an effective surgical treatment for PD in
advanced stages to rescue the patient 8% 92% Agree 1% 43% 55% Undetermined
Early initiation of appropriate treatment to delay PD
progression and improve quality of life 11% 89% Agree 0% 46% 54% Undetermined
All panelists (n = 75) answered all questions. Percentages of panelists in each category and consensus after the second round of votes are
shown. Bold % indicates that 70% consensus was achieved. MDU: movement disorders unit. PD: Parkinson’s disease. H: it will decrease;
=: it will not change; N: it will increase.
3.10. Resource Availability and General Needs
At present, there is limited availability of National Health System resources and
Neurology Services in all the items consulted. With a view to 2030, there was no clear
consensus on improvement, except for the availability of protocols and action plans, on
which panelists agreed that these will increase in the future (80%) (Table 7).
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Table 7. Resource availability and general needs: present and future.
Items YEAR 2020 TREND 2030
Currently There Is Sufficient Availability of This
Resource. By 2030, Availability of This Resource Will . . .
Resources in NHS and Neurology Services (StronglyDisagree
(Strongly)
Agree Consensus H = N Consensus
Number of nurses specialized in movement
disorders 99% 1% Disagree 4% 31% 65% Undetermined
New technologies available 97% 3% Disagree 1% 33% 66% Undetermined
Number of daycare centers for patients with PD 97% 3% Disagree 5% 36% 59% Undetermined
Time dedicated to the medical visit with the patient 97% 3% Disagree 1% 59% 40% Undetermined
Health care protocols and action plans 95% 5% Disagree 0% 20% 80% Increase N
Number of MDU units 95% 5% Disagree 0% 38% 62% Undetermined
Number of neurologists specialized in PD 95% 5% Disagree 1% 44% 55% Undetermined
General Needs
This Item Is a General Need in Management of
PD
By 2030 the Level of Satisfaction of This Need




Agree Consensus H = N Consensus
PD Awareness
Make patients visible to raise awareness and
knowledge of PD 5% 95% Agree 0% 39% 61% Undetermined
Work together on policies for the patient’s
reintegration into society, both socially and in the
workplace
8% 92% Agree 0% 42% 58% Undetermined
Raise awareness of the notable role that patient
associations have in the treatment of PD and
collaborate with them (e.g., raising public
awareness).
12% 88% Agree 0% 35% 65% Undetermined
Training and Education
Adequately train caregivers in the management of
the patient and the disease 1% 99% Agree 0% 36% 64% Undetermined
Adequately train patients in the management of their
own disease 1% 99% Agree 0% 38% 62% Undetermined
Promote and provide good training for neurologists
who assess the degree of disability 7% 93% Agree 0% 49% 51% Undetermined
Promote and provide good training for PCPs who
assess the degree of disability 11% 89% Agree 1% 55% 43% Undetermined
Resources
Have specialized protocols aimed at PCP and
general neurologists 4% 96% Agree 0% 46% 54% Undetermined
Ensure proper counseling and psychological support
for the patient and family throughout the disease
course
4% 96% Agree 0% 49% 51% Undetermined
Optimize the ratio patients per specialist
(neurologists . . . ) 4% 96% Agree 1% 51% 47% Undetermined
Provide more resources to hospital centers (MDU,
etc.) 5% 95% Agree 1% 45% 54% Undetermined
Involve more medical specialties (primary care,
geriatrics, etc.) in patient management 8% 92% Agree 0% 59% 41% Undetermined
Economic Impact
Optimize existing resources while minimizing the
economic impact on society and on the health system 3% 97% Agree 3% 56% 41% Undetermined
Reduce the economic impact on the caregiver 3% 97% Agree 5% 58% 37% Undetermined
Reduce the economic impact on the patient 3% 97% Agree 5% 59% 36% Undetermined
Research
Provide financial support for the research of new
treatments for PD 4% 96% Agree 3% 31% 67% Undetermined
Carry out detailed cost studies, including some
intangible costs of notorious importance (e.g.,
depression) as well as the costs associated with each
stage of the disease
9% 91% Agree 1% 44% 54% Undetermined
All panelists (n = 75) answered all questions. Percentages of panelists in each category and consensus after the second round of votes are
shown. Bold % indicates that 70% consensus was achieved. MDU: movement disorder units. PCP: primary care physician. PD: Parkinson’s
disease. H: it will decrease; =: it will not change; N: it will increase.
Brain Sci. 2021, 11, 1027 14 of 18
Regarding the need for PD awareness, training, education, resources, economic impact
and research, there was consensus on all items. Although it did not reach consensus for
the future, panelists predicted that the satisfaction of all these needs will increase by 2030
(Table 7).
4. Discussion
The outcomes of this project provide data on current diagnosis and management of
PD and its trends towards 2030 in Spain. This project included panelists with extensive
experience in PD and the main results show a future perspective of PD management similar
or better than nowadays.
PD is one of the most prevalent neurodegenerative diseases at present [1], and most
experts (92%) considered that prevalence will increase by 2030, in accordance with estimates
published in 2005, predicting that the number of individuals with PD would double by
2030 [4].
The Parkinson’s Disease Survey Observing the Quality of Care (Encuesta de Parkinson
Observando la Calidad Asistencial, EPOCA) study carried out in Spain showed that more
than half of patients get PD diagnosis between 1 and 5 years from the first symptom [17],
which is quite delayed, and this gap significantly increases in patients with early-onset.
Besides, according to SEN, up to 24% of PD patients have been misdiagnosed [3]. Therefore,
efforts should be put towards an early and accurate diagnosis of PD, shortening the time to
obtain PD diagnosis and rapid referral, as needs identified by study panelists.
Main criteria used for PD diagnosis are UK-PDSBB criteria and MDS criteria. When
UK-PDSBB criteria are used, non-motor symptoms are not included, although these symp-
toms significantly contribute to health status and quality of life in PD [18]. In contrast, new
MDS criteria [9] include motor symptoms and supportive criteria (non-motor symptoms).
In our study, a trend towards a change to PD definition including non-motor or atypical
symptoms, MDS criteria, and probably functional neuroimaging findings is observed.
Neuropsychiatric disorders (depression, apathy, sleep disturbances and anxiety) are
common in PD patients; however, are often underrecognized and undertreated. In particu-
lar, >80% of PD patients develop dementia after 20 years, and hallucinations are consistently
associated with progressive cognitive deterioration and dementia in PD [19–21]. According
with data form the literature, our expert panel agreed that these symptoms would become
relevant prognostic factors for PD patients in the future.
Given that PD is multifactorial and its etiopathogenesis is still unknown, no valid
biomarkers for diagnosis are currently available. At the present time, 90 independent PD
risk-associated mutations have been identified in more than 20 genes [22]; and it is still
on-going research. Panelists also reported that geneticists will have a more relevant role in
PD diagnosis, probably linked to the development of emerging technologies focused on the
improvements of the knowledge of genetic risk, genetic predisposition and genetic features.
Understanding the genetic factors that influence PD development will be important not
only for PD diagnosis, but also for developing new and personalized treatments.
A range of biomarkers, including imaging, biochemical or genetic biomarkers have
been proposed for PD diagnosis and prognosis; unfortunately, none can currently be used in
real life [23]. Nevertheless, panelists rely on their potential for improving PD management,
since they agreed that the use of CSF and plasma biomarkers and structural imaging as
prognostic markers of the disease will increase by 2030. Biomarkers could also provide
information on disease progression and treatment efficacy in the future, being involved
in monitoring follow-up. A recent study has identified a CSF biomarker (α-synuclein)
associated with increased risk of subsequent diagnosis of PD or dementia with Lewy
bodies [10] approaching this promising future.
Apart from biomarkers, new sensor-based and wearable and non-wearable, hybrid
technologies that can assess PD symptoms in an objective way will be useful for remote
monitoring of PD patients in the future. Although nowadays its use is still limited and
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further research is needed, panelists agreed that they will become an important support in
PD management [24,25].
The panelists determined that PD treatment in non-fluctuating patients should include
more than one drug; however, up to 60% of the experts indicate that high-dose levodopa
will continue to be used in monotherapy by 2030. Since its introduction in 1967, high-dose
oral levodopa regimen for PD treatment remains uncontested [26].
In the fluctuating PD patients, treatment with high-dose levodopa will remain un-
changed in the future, even though levodopa is associated with the appearance of motor
complications. Since recent reports indicate that levodopa use does not modify the dis-
ease course, its use as antiparkinsonian drug is expected to continue to be maintained in
the future, although low-dose levodopa is recommended to avoid dyskinesias. Current
guidelines recommend levodopa in combination; these results suggest the need for better
training about polytherapy benefits in these patients. There is also a trend towards a
greater use of levodopa + safinamide and the combination of levodopa + DA+ safinamide
not observed with other MAOI agents. This tendency might be explained by the proven
effect of safinamide in reducing motor and non-motor fluctuations, its low rate of adverse
events reported in several studies and importantly, the demonstrated effect of safinamide
in alleviating non-motor symptoms, including pain and depression, and on quality of life
impairment [27–30].
PD in later stages is characterized by the emergence of disabling motor and non-
motor symptoms, which are poorly controlled with conventional therapies and have a
significant impact on the patient’s health status [31]. In PD patients with an advanced
stage, panelists observed a trend towards an increase in the use of new therapies, in
particular DBS. This probably reflects that more patients will reach a device-based therapy
phase, or that the available therapies will not modify the course of the disease. There
is a significant need for developing treatments to modify the disease progression itself.
New therapies under development such as stem cell therapies or gene-therapy [32] and
a number of symptomatic and disease modifying therapies are currently being tested in
clinical trials [33]. The application of high intense focused ultrasound (HIFU) is a quite
new procedure that is being used for PD treatment. In our study, panelists agreed on its
increased use in the future in spite of the fact that it is quite a new technique. They also
considered HIFU as a useful tool for treating PD patients.
There is a general idea that both the appearance of motor and non-motor symptoms is
relevant for deciding on a change of treatment; however, regarding symptoms beyond the
CNS, experts did not consider them relevant when deciding on a change of treatment.
Guidelines state that a multidisciplinary team including professionals for assessing the
personal, family, work and social situation of the patient and create personalized treatments
for motor and non-motor symptoms with experience and adequate training is crucial for
therapy success [34]. The group of experts considered that the role of the neurologist
specialized in PD will become more relevant in the future, as well as the role of movement
disorder specialist nurses, highlighting the importance of specialization.
As with many other neurologic conditions, PD has a great impact on quality of life
and increases mortality among PD patients [35]. As the disability increases, PD symptoms
and the disease course affect not only patients, but also their families and caregivers.
Furthermore, it entails high economic burden with an estimated cost of €17,000 per patient
per year in Spain [13]. Pharmacological treatment was identified as the main driver (34%
of direct costs), and as the disease progresses, the need for symptomatic treatment grows.
PD unmet needs can be addressed through a comprehensive approach including
physical, psychological, social and financial aspects. Early actions on diagnosis, follow-up
and care planning can allow patients and caregivers to hamper the disease course and to
develop anticipatory strategies. In this vein, a recent study identified a desire of PD patients
and care partners to establish roadmaps as a guide for decision-making and planning [36].
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Limitations
The panelists participating in the study were representative of the clinical practice
across Spain, and provided detailed information regarding PD clinical management. Con-
sequently, results reflect the current management of PD and the vision for the future in a
populous European country; however, the conclusions of this study cannot be extrapolated
to other countries or cultural settings.
It has to be noted that the COVID-19 outbreak may have had an impact on the results,
given that the project was truncated by this pandemic and carried out in two different
scenarios. Besides, as with all Delphi studies, the results derived from the panel express an
opinion and do not analyze prospective or retrospective data. Finally, the questionnaire
was long, and bias due to tiredness cannot be excluded.
To our knowledge, this is the first study aiming to shed light on planning for future
PD management in Spain. This study highlights the unmet needs in diagnosis and treat-
ment and how crucial it is to establish recommendations on the diagnostic-therapeutic
management of PD to optimize and design future management strategies.
5. Conclusions
The global and, in particular, socio-economic impact of PD will continue to be very
important in all life dimensions of patients, family, caregivers, and in society in general,
especially for patients in more advanced stages.
The experts considered that there will be an improvement in diagnostic capacity,
follow-up and the development of innovative treatments, with fewer diagnostic errors and
earlier diagnosis. This will be due to improved access of patients to movement disorder
experts, and future studies on biomarkers will probably contribute to this improvement.
In prognosis, the use of certain biomarkers will be important; in monitoring, new tech-
nologies will have an impact; and in treatment, depending on the evolutionary stage of
the disease, the growing roles of expert nurses, neurologists, and other professionals (e.g.,
physiotherapists) will be very important, forming multidisciplinary teams that will move
towards a more individualized and technological medicine. In summary, this work offers
information that can help healthcare professionals to reflect individually on the care of PD
in their area and propose future strategies to improve the management of patients and
their environment (e.g., protocols, national plans, research management, social measures,
etc.), as well as advance in knowledge and research.
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dase B; (b) Perceived utility of non-pharmacological investigational therapies. HIFU: high-intensity
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